An urgent recall has been issued for Silintan capsules by Anthony Trinh, 123Herbals LLC, following FDA confirmation that the product contains undisclosed meloxicam. This announcement may concern healthcare professionals specializing in patient safety, regulatory compliance teams, and retailers who distribute dietary supplements.
Why Was the Recall Issued?
On January 7, 2026, Anthony Trinh, 123Herbals LLC, initiated a voluntary nationwide recall of its Silintan capsules after FDA analysis confirmed the unexpected presence of meloxicam. This substance is a nonsteroidal anti-inflammatory drug (NSAID) approved for treating osteoarthritis pain but is prohibited in dietary supplements. As no safety or efficacy data for this application has been established, meloxicam’s inclusion categorizes Silintan as an unapproved new drug and necessitates product withdrawal.
What Are the Risks?
Exposure to meloxicam in excess of the approved daily limit of 15 mg poses significant health risks. Documented complications include life-threatening cardiovascular events such as blood clots, heart attacks, and strokes. Additional risks involve gastrointestinal bleeding, hypersensitivity reactions, ulceration, and kidney injury. Elderly patients and individuals taking blood thinners or other NSAIDs are especially vulnerable due to heightened bleeding risk and potential drug-drug interactions.
At the time of the recall announcement, no adverse events linked to Silintan capsules had been reported to Anthony Trinh, 123Herbals LLC.
Which Products Are Affected?
The recall applies to all lot numbers and expiration dates of Silintan capsules marketed online nationwide via the retailer’s official website (123herbals.com). The product, designed for relief of joint and body aches, is packaged in 25-count bottles displaying a blue label. Customers are urged to discontinue use and either return the product to the original point of purchase or safely discard it. Professional medical consultation is recommended for consumers who suspect health concerns stemming from the use of these capsules.
How to Contact 123Herbals LLC
For questions related to this recall, Anthony Trinh, 123Herbals LLC provides the following contact options:
- Email: hello@123herbals.com
- Phone: 1-626-656-3202 (available Monday – Friday, 8 am to 5 pm PT)
Website customers can return affected products by mail to: 300 West Valley Blvd. P.O. Box 1925, Alhambra, CA 91803.
How to Report Adverse Events
The FDA encourages reporting adverse reactions or product quality issues through its MedWatch Adverse Event Reporting program. Accessible options include:
- Online submission via FDA MedWatch
- Mail or fax submission, with forms available for download or by calling 1-800-332-1088.
Conclusion
Healthcare and regulatory professionals should take note of this recall and ensure the public is informed about the risks associated with Silintan capsules. Prompt action to halt distribution and facilitate safe disposal will mitigate potential harm to consumers.
Disclaimer
This post is intended for informational purposes and does not serve as legal or regulatory advice. Consult with appropriate specialists for guidance specific to your situation.
Mandatory FDA Line
For full information about the FDA announcement, see the link below.
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/anthony-trinh-123herbals-llc-123herbalscom-issues-nationwide-recall-silintan-capsules-due-presence